VEGFR2/CD309 Rekombinanter Antikörper
VEGFR2/CD309 Rekombinant Antikörper für WB, IHC, FC, Indirect ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human
Anwendung
WB, IHC, FC, Indirect ELISA
Konjugation
Unkonjugiert
CloneNo.
230238D7
Kat-Nr. : 83049-4-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
83049-4-PBS bindet in WB, IHC, FC, Indirect ELISA VEGFR2/CD309 und zeigt Reaktivität mit human
Getestete Reaktivität | human |
Wirt / Isotyp | Kaninchen / IgG |
Klonalität | Rekombinant |
Typ | Antikörper |
Immunogen | VEGFR2/CD309 fusion protein Eg0218 |
Vollständiger Name | kinase insert domain receptor (a type III receptor tyrosine kinase) |
Berechnetes Molekulargewicht | 152 kDa |
Beobachtetes Molekulargewicht | 150 kDa, 230 kDa |
GenBank-Zugangsnummer | NM_002253 |
Gene symbol | KDR |
Gene ID (NCBI) | 3791 |
Konjugation | Unkonjugiert |
Form | Liquid |
Reinigungsmethode | Protein-A-Reinigung |
Lagerungspuffer | PBS only |
Lagerungsbedingungen | Store at -80°C. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
KDR, also named as VEGFR-2, FLK1 and CD309, is a receptor for VEGF or VEGFC. KDR which belongs to the protein kinase superfamily, has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. KDR functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. Mutations of this gene are implicated in infantile capillary hemangiomas.